BRPI0813513A2 - Terapia específica e medicamento usando ligantes de integrina para tratamento de câncer - Google Patents
Terapia específica e medicamento usando ligantes de integrina para tratamento de câncerInfo
- Publication number
- BRPI0813513A2 BRPI0813513A2 BRPI0813513-4A2A BRPI0813513A BRPI0813513A2 BR PI0813513 A2 BRPI0813513 A2 BR PI0813513A2 BR PI0813513 A BRPI0813513 A BR PI0813513A BR PI0813513 A2 BRPI0813513 A2 BR PI0813513A2
- Authority
- BR
- Brazil
- Prior art keywords
- integrine
- links
- cancer treatment
- medicinal product
- specific therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07014070 | 2007-07-18 | ||
PCT/EP2008/005831 WO2009010287A2 (en) | 2007-07-18 | 2008-07-17 | Specific therapy and medicament using integrin ligands for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0813513A2 true BRPI0813513A2 (pt) | 2015-01-06 |
Family
ID=39402737
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0806596-9A BRPI0806596A2 (pt) | 2007-01-18 | 2008-01-17 | medicamento e terapia especÍfica usando-se ligantes de integrina para o tratamento de cÂncer |
BRPI0813513-4A2A BRPI0813513A2 (pt) | 2007-07-18 | 2008-07-17 | Terapia específica e medicamento usando ligantes de integrina para tratamento de câncer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0806596-9A BRPI0806596A2 (pt) | 2007-01-18 | 2008-01-17 | medicamento e terapia especÍfica usando-se ligantes de integrina para o tratamento de cÂncer |
Country Status (19)
Country | Link |
---|---|
US (2) | US20100069302A1 (pt) |
EP (4) | EP2441464B1 (pt) |
JP (3) | JP2010516645A (pt) |
KR (2) | KR20090108713A (pt) |
CN (2) | CN101588812A (pt) |
AU (2) | AU2008207095B2 (pt) |
BR (2) | BRPI0806596A2 (pt) |
CA (2) | CA2675813A1 (pt) |
CO (1) | CO6382135A2 (pt) |
DK (1) | DK2101805T3 (pt) |
EA (2) | EA017864B1 (pt) |
EC (1) | ECSP109969A (pt) |
ES (2) | ES2399159T3 (pt) |
IL (1) | IL199696A0 (pt) |
MX (1) | MX2009007597A (pt) |
PL (1) | PL2101805T3 (pt) |
PT (1) | PT2101805E (pt) |
WO (2) | WO2008087025A2 (pt) |
ZA (1) | ZA200905703B (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2101805E (pt) * | 2007-01-18 | 2013-01-31 | Merck Patent Gmbh | Terapia específica e medicamento usando ligandos integrina para tratar o cancro |
US20110230423A1 (en) * | 2008-11-20 | 2011-09-22 | Martin Andreas Picard | Therapy and medicament using integrin ligands for treating cancer |
MX2011012491A (es) * | 2009-05-25 | 2011-12-14 | Merck Patent Gmbh | Administracion continua de cilengitida en tratamientos contra el cancer. |
CA2775601C (en) | 2009-09-28 | 2017-10-03 | Qilu Pharmaceutical Co., Ltd | 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors |
WO2011146819A2 (en) * | 2010-05-20 | 2011-11-24 | Dmd Therapies, Llc | METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES |
SG11201504392XA (en) * | 2012-12-07 | 2015-07-30 | Baxter Int | Anti-mif antibody cell migration assay |
WO2014205179A1 (en) * | 2013-06-21 | 2014-12-24 | The General Hospital Corporation | Ribonucleotide reductase inhibitors sensitize tumor cells to dna damaging agents |
KR101579054B1 (ko) * | 2014-03-26 | 2015-12-21 | 한국원자력의학원 | 포도필로톡신 아세테이트를 유효 성분으로 포함하는 방사선치료 증진제 |
EP3194972B1 (en) * | 2014-09-17 | 2021-04-14 | Merck Patent GmbH | A method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases |
WO2016067010A1 (en) * | 2014-10-30 | 2016-05-06 | Big Dna Ltd | Combination therapy |
EP3207937A1 (en) | 2016-02-17 | 2017-08-23 | Royal College of Surgeons in Ireland | A method of treating or preventing sepsis |
CN105906692A (zh) * | 2016-03-11 | 2016-08-31 | 李书鹏 | cRGD-厄洛替尼缀合物及其制备方法 |
GB2554333A (en) * | 2016-04-26 | 2018-04-04 | Big Dna Ltd | Combination therapy |
US20200271654A1 (en) * | 2017-02-06 | 2020-08-27 | Expression Pathology, Inc. | Quantifying MGMT Protein For Optimal Cancer Therapy |
WO2022157336A1 (en) | 2021-01-22 | 2022-07-28 | Royal College Of Surgeons In Ireland | Treatment of coronavirus |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US701446A (en) | 1901-12-30 | 1902-06-03 | Lewis W Wooten | Cotton-chopper. |
US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US5260291A (en) | 1981-08-24 | 1993-11-09 | Cancer Research Campaign Technology Limited | Tetrazine derivatives |
US4661111A (en) | 1982-08-04 | 1987-04-28 | La Jolla Cancer Research Foundation | Polypeptide |
US4792525A (en) | 1982-08-04 | 1988-12-20 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4589881A (en) | 1982-08-04 | 1986-05-20 | La Jolla Cancer Research Foundation | Polypeptide |
US4614517A (en) | 1982-08-04 | 1986-09-30 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4578079A (en) | 1982-08-04 | 1986-03-25 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4517686A (en) | 1982-08-04 | 1985-05-21 | La Jolla Cancer Research Foundation | Polypeptide |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
CA2062795A1 (en) | 1989-06-29 | 1990-12-30 | Michael W. Fanger | Bispecific reagents for aids therapy |
WO1991003493A1 (en) | 1989-08-29 | 1991-03-21 | The University Of Southampton | Bi-or trispecific (fab)3 or (fab)4 conjugates |
AU667460B2 (en) | 1990-10-05 | 1996-03-28 | Medarex, Inc. | Targeted immunostimulation with bispecific reagents |
EP0563214A4 (en) | 1990-12-04 | 1994-08-17 | Wistar Inst | Bifunctional antibodies and method of preparing same |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
EP1514934B1 (en) | 1992-02-06 | 2008-12-31 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
US5407804A (en) | 1992-05-22 | 1995-04-18 | Applied Genetics Inc. | Assays for O6 -methylguanine-DNA methyltransferase |
GB9224888D0 (en) | 1992-11-27 | 1993-01-13 | Univ Singapore | Monoclonal antibody |
DE69329974T2 (de) | 1992-12-04 | 2001-07-19 | Medical Research Council, London | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
US5753230A (en) | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
US5504101A (en) | 1994-05-06 | 1996-04-02 | Allelix Biopharmaceuticals, Inc. | 5-HT-1D receptor ligands |
ES2186720T3 (es) | 1994-05-27 | 2003-05-16 | Merck & Co Inc | Composiciones para inhibir la reabsorcion osea mediada por osteoclastos. |
PL318199A1 (en) | 1994-06-29 | 1997-05-26 | Smithkline Beecham Corp | Antagonists of vitronectin receptors |
JPH10504807A (ja) | 1994-06-29 | 1998-05-12 | スミスクライン・ビーチャム・コーポレイション | ビトロネクチン受容体拮抗剤 |
IT1271688B (it) | 1994-08-04 | 1997-06-04 | Menarini Ricerche Sud Spa | Molecole ibride per il trattamento antitumorale loro preparazione e loro uso in composizioni farmaceutiche |
AU2989695A (en) * | 1994-08-08 | 2000-03-07 | Debiopharm S.A. | Pharmaceutically stable oxaliplatinum preparation |
US6008214A (en) | 1994-08-22 | 1999-12-28 | Smithkline Beecham Corporation | Bicyclic compounds |
WO1996026190A1 (en) | 1995-02-22 | 1996-08-29 | Smithkline Beecham Corporation | Integrin receptor antagonists |
US5780426A (en) | 1995-06-07 | 1998-07-14 | Ixsys, Incorporated | Fivemer cyclic peptide inhibitors of diseases involving αv β3 |
JP3960482B2 (ja) | 1995-06-29 | 2007-08-15 | スミスクライン・ビーチャム・コーポレイション | インテグリン受容体アンタゴニスト |
DE19534177A1 (de) | 1995-09-15 | 1997-03-20 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
KR19990076878A (ko) | 1995-12-29 | 1999-10-25 | 스티븐 베네티아너 | 비트로넥틴 수용체 길항제 |
KR19990076876A (ko) | 1995-12-29 | 1999-10-25 | 스티븐 베네티아너 | 비트로넥틴 수용체 길항제 |
CZ203898A3 (cs) | 1995-12-29 | 1999-03-17 | Smithkline Beecham Corporation | Antagonista vitronektinového receptoru, farmaceutický přípravek s jeho obsahem, způsob a použití |
AP806A (en) | 1996-03-20 | 2000-01-28 | Aventis Pharma Sa | Tricyclic compounds having activity specific for integrins, particularly avB3 integrins, method for preparing same, intermediates therefor, use of said compounds as drugs, and pharmaceutical compositions containing same. |
US5925655A (en) | 1996-04-10 | 1999-07-20 | Merck & Co., Inc. | αv β3 antagonists |
ATE227268T1 (de) | 1996-04-10 | 2002-11-15 | Merck & Co Inc | Alpha v beta 3 antagonisten |
WO1997041844A1 (en) | 1996-05-09 | 1997-11-13 | Alcon Laboratories, Inc. | Combinations of angiostatic compounds |
BR9709514A (pt) * | 1996-05-31 | 1999-08-10 | Scripps Research Inst | Processo e composições úteis para a inibição de angiogénese mediada por alfa beta |
US5786146A (en) | 1996-06-03 | 1998-07-28 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
US6017704A (en) | 1996-06-03 | 2000-01-25 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
AU724191B2 (en) | 1996-08-29 | 2000-09-14 | Merck & Co., Inc. | Integrin antagonists |
US5981546A (en) | 1996-08-29 | 1999-11-09 | Merck & Co., Inc. | Integrin antagonists |
WO1998015278A1 (en) | 1996-10-07 | 1998-04-16 | Smithkline Beecham Corporation | Method for stimulating bone formation |
US5919792A (en) | 1996-10-30 | 1999-07-06 | Merck & Co., Inc. | Integrin antagonists |
JP2001504456A (ja) | 1996-10-30 | 2001-04-03 | メルク エンド カンパニー インコーポレーテッド | インテグリン拮抗薬 |
JP2001503060A (ja) | 1996-10-30 | 2001-03-06 | メルク エンド カンパニー インコーポレーテッド | インテグリン拮抗薬 |
AU5596298A (en) | 1996-12-09 | 1998-07-03 | Cor Therapeutics, Inc. | Integrin antagonists |
DE19653647A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
DE19653645A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
DE19653646A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung |
CO4920232A1 (es) | 1997-01-08 | 2000-05-29 | Smithkline Beecham Corp | Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin |
WO1998031359A1 (en) | 1997-01-17 | 1998-07-23 | Merck & Co., Inc. | Integrin antagonists |
DK0979281T3 (da) | 1997-05-02 | 2005-11-21 | Genentech Inc | Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele |
CA2297910A1 (en) | 1997-07-25 | 1999-02-04 | Smithkline Beecham Corporation | Vitronectin receptor antagonist |
CA2298544A1 (en) | 1997-08-04 | 1999-02-11 | Smithkline Beecham Corporation | Integrin receptor antagonists |
CA2304117A1 (en) | 1997-09-04 | 1999-03-11 | Dirk A. Heerding | Integrin receptor antagonists |
PE122699A1 (es) | 1997-09-19 | 2000-02-12 | Smithkline Beecham Corp | Antagonistas de receptores de vitronectina |
FR2768734B1 (fr) | 1997-09-24 | 2000-01-28 | Roussel Uclaf | Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant |
AU9577498A (en) | 1997-09-24 | 1999-04-12 | Smithkline Beecham Corporation | Vitronectin receptor antagonist |
IL135188A0 (en) | 1997-09-24 | 2001-05-20 | Smithkline Beecham Corp | Vitronectin receptor antagonist |
FR2768736B1 (fr) | 1997-09-24 | 2000-05-26 | Roussel Uclaf | Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant |
US6017926A (en) | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
AU741769B2 (en) | 1997-12-17 | 2001-12-06 | Merck Sharp & Dohme Corp. | Integrin receptor antagonists |
CA2315370A1 (en) | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Integrin receptor antagonists |
NZ504893A (en) | 1997-12-17 | 2002-10-25 | Merck & Co Inc | 5, 6, 7, 8-Tetrahydro-[1,8]-naphthyridin-2-yl derivatives useful as integrin receptor antagonists |
US6048861A (en) | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
ATE299023T1 (de) | 1997-12-17 | 2005-07-15 | Merck & Co Inc | Integrinrezeptor antagonisten |
EP1049718B1 (en) | 1998-01-23 | 2006-04-05 | MERCK PATENT GmbH | Use of the antibody 271.14d9.f8 (dsm acc2331) to inhibit in vitro alphavbeta6-integrin attachment to fibronectin |
WO2000006169A1 (en) | 1998-07-29 | 2000-02-10 | Merck & Co., Inc. | Integrin receptor antagonists |
EP1105389A4 (en) | 1998-08-13 | 2001-10-17 | Merck & Co Inc | INTEGRIN RECEPTOR ANTAGONISTS |
DE19842415A1 (de) | 1998-09-16 | 2000-03-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung |
BR9916518A (pt) * | 1998-12-23 | 2002-01-29 | Searle & Co | Método para tratar ou prevenir um distúrbio de neoplasia em um mamìfero em necessidade de tal tratamento ou prevenção, e, combinação compreendendo um inibidor de ciclooxigenase-2 e um ou mais agentes anti-neoplásticos |
BR0011108A (pt) | 1999-06-02 | 2002-03-19 | Merck & Co Inc | Composto, composição farmacêutica, e, processos de eliciar um efeito antagonizante do receptor da integrina, de tratamento ou prevenção da osteoporose, de tratamento ou prevenção de uma condição mediada por antagonismo de um receptor de integrina, de inibição da reabsorção óssea em um mamìfero em necessidade do mesmo, e de tratamento do desenvolvimento tumoral |
AU2001261724A1 (en) * | 2000-05-19 | 2001-12-03 | The Board Of Trustees Of The Leland Stanford Junior University | Viral vectors useful in induction of humoral or cellular immunity |
EP1328656A4 (en) * | 2000-09-29 | 2005-09-14 | Univ Johns Hopkins Med | METHOD FOR PREDICTING THE CLINICAL RESPONSE TO CHEMOTHERAPY WITH ALKYLATING AGENTS |
MXPA03006121A (es) * | 2001-01-09 | 2003-09-10 | Merck Patent Gmbh | Terapia de combinacion usando inhibidores del receptor tirosin-cinasa e inhibidores de la angiogenesis. |
JP4660067B2 (ja) * | 2001-04-24 | 2011-03-30 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗血管新生剤とTNFαとを用いる組合せ療法 |
DE10228049A1 (de) * | 2002-06-24 | 2004-01-15 | Merck Patent Gmbh | Flüssige Zubereitung enthaltend Oligopeptide |
US20060084666A1 (en) * | 2004-10-18 | 2006-04-20 | Harari Paul M | Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor |
EA016817B1 (ru) * | 2006-01-18 | 2012-07-30 | Мерк Патент Гмбх | Специфическая терапия, использующая интегриновые лиганды для лечения рака |
PT2101805E (pt) * | 2007-01-18 | 2013-01-31 | Merck Patent Gmbh | Terapia específica e medicamento usando ligandos integrina para tratar o cancro |
-
2008
- 2008-01-17 PT PT87070934T patent/PT2101805E/pt unknown
- 2008-01-17 EP EP11009510.6A patent/EP2441464B1/en not_active Not-in-force
- 2008-01-17 WO PCT/EP2008/000328 patent/WO2008087025A2/en active Application Filing
- 2008-01-17 MX MX2009007597A patent/MX2009007597A/es active IP Right Grant
- 2008-01-17 US US12/523,491 patent/US20100069302A1/en not_active Abandoned
- 2008-01-17 BR BRPI0806596-9A patent/BRPI0806596A2/pt not_active IP Right Cessation
- 2008-01-17 EP EP08707093A patent/EP2101805B1/en not_active Not-in-force
- 2008-01-17 CA CA002675813A patent/CA2675813A1/en not_active Abandoned
- 2008-01-17 ES ES08707093T patent/ES2399159T3/es active Active
- 2008-01-17 PL PL08707093T patent/PL2101805T3/pl unknown
- 2008-01-17 KR KR1020097017119A patent/KR20090108713A/ko not_active Application Discontinuation
- 2008-01-17 AU AU2008207095A patent/AU2008207095B2/en not_active Ceased
- 2008-01-17 ES ES11009510.6T patent/ES2472450T3/es active Active
- 2008-01-17 CN CNA2008800024456A patent/CN101588812A/zh active Pending
- 2008-01-17 DK DK08707093.4T patent/DK2101805T3/da active
- 2008-01-17 JP JP2009545872A patent/JP2010516645A/ja active Pending
- 2008-01-17 EA EA200900912A patent/EA017864B1/ru not_active IP Right Cessation
- 2008-07-17 CN CN200880024802A patent/CN101743013A/zh active Pending
- 2008-07-17 JP JP2010516420A patent/JP2010533665A/ja active Pending
- 2008-07-17 US US12/668,823 patent/US20100190957A1/en not_active Abandoned
- 2008-07-17 WO PCT/EP2008/005831 patent/WO2009010287A2/en active Application Filing
- 2008-07-17 EP EP12007334.1A patent/EP2578225A1/en not_active Withdrawn
- 2008-07-17 CA CA2693862A patent/CA2693862A1/en not_active Abandoned
- 2008-07-17 EA EA201000127A patent/EA201000127A1/ru unknown
- 2008-07-17 AU AU2008277904A patent/AU2008277904A1/en not_active Abandoned
- 2008-07-17 KR KR1020107003515A patent/KR20100043242A/ko not_active Application Discontinuation
- 2008-07-17 EP EP08774010A patent/EP2164506A2/en not_active Ceased
- 2008-07-17 BR BRPI0813513-4A2A patent/BRPI0813513A2/pt not_active IP Right Cessation
-
2009
- 2009-07-05 IL IL199696A patent/IL199696A0/en unknown
- 2009-08-17 ZA ZA200905703A patent/ZA200905703B/xx unknown
-
2010
- 2010-01-15 CO CO10003771A patent/CO6382135A2/es not_active Application Discontinuation
- 2010-02-17 EC EC2010009969A patent/ECSP109969A/es unknown
-
2013
- 2013-10-18 JP JP2013217677A patent/JP2014015482A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0813513A2 (pt) | Terapia específica e medicamento usando ligantes de integrina para tratamento de câncer | |
BRPI0821660A2 (pt) | Combinações de agentes terapêuticos para tratamento de câncer | |
BRPI0922771A2 (pt) | agentes indutores de apoptose seletivos para bcl-2 para o tratamento de câncer e doenças imunes | |
BRPI0810816A2 (pt) | Medicamento e métodos para tratar doenças auto-imune e câncer | |
BRPI0821779A2 (pt) | tratamento terapêutico de câncer | |
BRPI0811589A2 (pt) | Composição farmacêutica e método para tratar câncer | |
BR112012018947A2 (pt) | composição farmacêutica para tratamento e\ou prevenção do cancêr | |
BRPI0810082A2 (pt) | 3-imidazolil-indóis para o tratamento de doenças proliferativas | |
DK2121139T3 (da) | Formulations for cancer treatment | |
EP2166837A4 (en) | DRUG COMBINATION USEFUL FOR THE TREATMENT OF SKIN DISORDERS | |
BRPI0807987A2 (pt) | Terapia de combinação para tratamento de distúrbios imunes. | |
EP2165715A4 (en) | THERAPEUTIC AGENT FOR CANCER AND METHOD FOR TREATING CANCER | |
EP2046973A4 (en) | METHODS OF IDENTIFYING, EVALUATING, AND TREATING PATIENTS SUBJECTED TO ANTICANCER THERAPY | |
BRPI0816712A2 (pt) | terapia de intervalo para o tratamento de tinnitus | |
EP2125002A4 (en) | TREATMENT OF SKIN CANCER | |
BRPI0821248A2 (pt) | Inibidores de cinesina como fármacos terapêuticos para câncer | |
ZA200907245B (en) | Phthalazinone derivatives and their use as medicament to treat cancer | |
IL205608A (en) | History of s-triazole-1-ram-benzamide and their use in the preparation of pain medication | |
BRPI0820477A2 (pt) | Compostos de benzodiazepinona úteis no tratamento de afecções da pele | |
EP2219448A4 (en) | THERAPEUTIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASES AND SUFFERINGS | |
BR112012031836A2 (pt) | combinação farmacêutica para o tratamento da dor | |
EP2148675A4 (en) | ANTI-CANCER FOR THE DIAGNOSIS AND TREATMENT OF CANCER | |
BRPI1010086A2 (pt) | método e produtos para tratamento de doenças | |
BRPI1009448A2 (pt) | combinações farmacêuticas compreendendo edea119/bay 869766 para o tratamento de cânceres específicos | |
BRPI0922367A2 (pt) | enzastaurin para o tratamento de câncer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |